LNAI

Lunai Bioworks

1.27 USD
+0.06
4.96%
At close Updated Oct 21, 4:00 PM EDT
1 day
4.96%
5 days
4.96%
1 month
-21.6%
3 months
-58.77%
6 months
-68.41%
Year to date
-83.36%
1 year
-78.44%
5 years
-96.22%
10 years
-98.49%
 

About: Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Employees: 29

0
Funds holding %
of 7,499 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™